Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion

A retrospective European group for blood and marrow transplantation analysis

Johannes Schetelig, Anja Van Biezen, Ronald Brand, Dolores Caballero, Rodrigo Martino, Maija Itala, José A. García-Marco, Liisa Volin, Norbert Schmitz, Rainer Schwerdtfeger, Arnold Ganser, Francesco Onida, Brigitte Mohr, Stephan Stilgenbauer, Martin Bornhäuser, Theo De Witte, Peter Dreger

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

Purpose: Patients with chronic lymphocytic leukemia (CLL) and 17p deletion (17p-) have a poor prognosis. Although allogeneic hematopoietic stem-cell transplantation (HCT) has the potential to cure patients with advanced CLL, it is not known whether this holds true for patients with 17p- CLL. Patients and Methods: Baseline data from patients, for whom information on the presence of 17p- CLL was available, were downloaded from the European Group for Blood and Marrow Transplantation database. Additional information on the course of CLL and follow-up was collected with a questionnaire. Results: A total of 44 patients with 17p- CLL received allogeneic HCT between March 1995 and July 2006 from a matched sibling (n = 24) or an alternative donor (n = 20). 17p- CLL had been diagnosed by fluorescent in situ hybridization in 82% of patients and by conventional banding in 18% of patients. The median age was 54 years. Before HCT, a median of three lines of chemotherapy had been administered. At HCT, 53% of patients were in remission. Reduced-intensity conditioning was applied in 89% of patients. Acute, grade 2 to 4 graft-versus-host disease (GVHD) occurred in 43% of patients, and extensive chronic GVHD occurred in 53% of patients. At last follow-up, 19 patients were alive, with a median observation time of 39 months (range, 18 to 101 months). Three-year overall survival and progression-free survival rates were 44% and 37%, respectively. The cumulative incidence of progressive disease at 4 years was 34%. No late relapse occurred in nine patients with a follow-up longer than 4 years. Conclusion: Allogeneic HCT has the potential to induce long-term disease-free survival in patients with 17p- CLL.

Original languageEnglish
Pages (from-to)5094-5100
Number of pages7
JournalJournal of Clinical Oncology
Volume26
Issue number31
DOIs
Publication statusPublished - Nov 1 2008

Fingerprint

Hematopoietic Stem Cell Transplantation
B-Cell Chronic Lymphocytic Leukemia
Blood Group Antigens
Transplantation
Bone Marrow
Graft vs Host Disease
Disease-Free Survival
Fluorescence In Situ Hybridization
Siblings

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion : A retrospective European group for blood and marrow transplantation analysis. / Schetelig, Johannes; Van Biezen, Anja; Brand, Ronald; Caballero, Dolores; Martino, Rodrigo; Itala, Maija; García-Marco, José A.; Volin, Liisa; Schmitz, Norbert; Schwerdtfeger, Rainer; Ganser, Arnold; Onida, Francesco; Mohr, Brigitte; Stilgenbauer, Stephan; Bornhäuser, Martin; De Witte, Theo; Dreger, Peter.

In: Journal of Clinical Oncology, Vol. 26, No. 31, 01.11.2008, p. 5094-5100.

Research output: Contribution to journalArticle

Schetelig, J, Van Biezen, A, Brand, R, Caballero, D, Martino, R, Itala, M, García-Marco, JA, Volin, L, Schmitz, N, Schwerdtfeger, R, Ganser, A, Onida, F, Mohr, B, Stilgenbauer, S, Bornhäuser, M, De Witte, T & Dreger, P 2008, 'Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: A retrospective European group for blood and marrow transplantation analysis', Journal of Clinical Oncology, vol. 26, no. 31, pp. 5094-5100. https://doi.org/10.1200/JCO.2008.16.2982
Schetelig, Johannes ; Van Biezen, Anja ; Brand, Ronald ; Caballero, Dolores ; Martino, Rodrigo ; Itala, Maija ; García-Marco, José A. ; Volin, Liisa ; Schmitz, Norbert ; Schwerdtfeger, Rainer ; Ganser, Arnold ; Onida, Francesco ; Mohr, Brigitte ; Stilgenbauer, Stephan ; Bornhäuser, Martin ; De Witte, Theo ; Dreger, Peter. / Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion : A retrospective European group for blood and marrow transplantation analysis. In: Journal of Clinical Oncology. 2008 ; Vol. 26, No. 31. pp. 5094-5100.
@article{1736151bbecc477c833e84c60c1bad3d,
title = "Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: A retrospective European group for blood and marrow transplantation analysis",
abstract = "Purpose: Patients with chronic lymphocytic leukemia (CLL) and 17p deletion (17p-) have a poor prognosis. Although allogeneic hematopoietic stem-cell transplantation (HCT) has the potential to cure patients with advanced CLL, it is not known whether this holds true for patients with 17p- CLL. Patients and Methods: Baseline data from patients, for whom information on the presence of 17p- CLL was available, were downloaded from the European Group for Blood and Marrow Transplantation database. Additional information on the course of CLL and follow-up was collected with a questionnaire. Results: A total of 44 patients with 17p- CLL received allogeneic HCT between March 1995 and July 2006 from a matched sibling (n = 24) or an alternative donor (n = 20). 17p- CLL had been diagnosed by fluorescent in situ hybridization in 82{\%} of patients and by conventional banding in 18{\%} of patients. The median age was 54 years. Before HCT, a median of three lines of chemotherapy had been administered. At HCT, 53{\%} of patients were in remission. Reduced-intensity conditioning was applied in 89{\%} of patients. Acute, grade 2 to 4 graft-versus-host disease (GVHD) occurred in 43{\%} of patients, and extensive chronic GVHD occurred in 53{\%} of patients. At last follow-up, 19 patients were alive, with a median observation time of 39 months (range, 18 to 101 months). Three-year overall survival and progression-free survival rates were 44{\%} and 37{\%}, respectively. The cumulative incidence of progressive disease at 4 years was 34{\%}. No late relapse occurred in nine patients with a follow-up longer than 4 years. Conclusion: Allogeneic HCT has the potential to induce long-term disease-free survival in patients with 17p- CLL.",
author = "Johannes Schetelig and {Van Biezen}, Anja and Ronald Brand and Dolores Caballero and Rodrigo Martino and Maija Itala and Garc{\'i}a-Marco, {Jos{\'e} A.} and Liisa Volin and Norbert Schmitz and Rainer Schwerdtfeger and Arnold Ganser and Francesco Onida and Brigitte Mohr and Stephan Stilgenbauer and Martin Bornh{\"a}user and {De Witte}, Theo and Peter Dreger",
year = "2008",
month = "11",
day = "1",
doi = "10.1200/JCO.2008.16.2982",
language = "English",
volume = "26",
pages = "5094--5100",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "31",

}

TY - JOUR

T1 - Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion

T2 - A retrospective European group for blood and marrow transplantation analysis

AU - Schetelig, Johannes

AU - Van Biezen, Anja

AU - Brand, Ronald

AU - Caballero, Dolores

AU - Martino, Rodrigo

AU - Itala, Maija

AU - García-Marco, José A.

AU - Volin, Liisa

AU - Schmitz, Norbert

AU - Schwerdtfeger, Rainer

AU - Ganser, Arnold

AU - Onida, Francesco

AU - Mohr, Brigitte

AU - Stilgenbauer, Stephan

AU - Bornhäuser, Martin

AU - De Witte, Theo

AU - Dreger, Peter

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Purpose: Patients with chronic lymphocytic leukemia (CLL) and 17p deletion (17p-) have a poor prognosis. Although allogeneic hematopoietic stem-cell transplantation (HCT) has the potential to cure patients with advanced CLL, it is not known whether this holds true for patients with 17p- CLL. Patients and Methods: Baseline data from patients, for whom information on the presence of 17p- CLL was available, were downloaded from the European Group for Blood and Marrow Transplantation database. Additional information on the course of CLL and follow-up was collected with a questionnaire. Results: A total of 44 patients with 17p- CLL received allogeneic HCT between March 1995 and July 2006 from a matched sibling (n = 24) or an alternative donor (n = 20). 17p- CLL had been diagnosed by fluorescent in situ hybridization in 82% of patients and by conventional banding in 18% of patients. The median age was 54 years. Before HCT, a median of three lines of chemotherapy had been administered. At HCT, 53% of patients were in remission. Reduced-intensity conditioning was applied in 89% of patients. Acute, grade 2 to 4 graft-versus-host disease (GVHD) occurred in 43% of patients, and extensive chronic GVHD occurred in 53% of patients. At last follow-up, 19 patients were alive, with a median observation time of 39 months (range, 18 to 101 months). Three-year overall survival and progression-free survival rates were 44% and 37%, respectively. The cumulative incidence of progressive disease at 4 years was 34%. No late relapse occurred in nine patients with a follow-up longer than 4 years. Conclusion: Allogeneic HCT has the potential to induce long-term disease-free survival in patients with 17p- CLL.

AB - Purpose: Patients with chronic lymphocytic leukemia (CLL) and 17p deletion (17p-) have a poor prognosis. Although allogeneic hematopoietic stem-cell transplantation (HCT) has the potential to cure patients with advanced CLL, it is not known whether this holds true for patients with 17p- CLL. Patients and Methods: Baseline data from patients, for whom information on the presence of 17p- CLL was available, were downloaded from the European Group for Blood and Marrow Transplantation database. Additional information on the course of CLL and follow-up was collected with a questionnaire. Results: A total of 44 patients with 17p- CLL received allogeneic HCT between March 1995 and July 2006 from a matched sibling (n = 24) or an alternative donor (n = 20). 17p- CLL had been diagnosed by fluorescent in situ hybridization in 82% of patients and by conventional banding in 18% of patients. The median age was 54 years. Before HCT, a median of three lines of chemotherapy had been administered. At HCT, 53% of patients were in remission. Reduced-intensity conditioning was applied in 89% of patients. Acute, grade 2 to 4 graft-versus-host disease (GVHD) occurred in 43% of patients, and extensive chronic GVHD occurred in 53% of patients. At last follow-up, 19 patients were alive, with a median observation time of 39 months (range, 18 to 101 months). Three-year overall survival and progression-free survival rates were 44% and 37%, respectively. The cumulative incidence of progressive disease at 4 years was 34%. No late relapse occurred in nine patients with a follow-up longer than 4 years. Conclusion: Allogeneic HCT has the potential to induce long-term disease-free survival in patients with 17p- CLL.

UR - http://www.scopus.com/inward/record.url?scp=55549097826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55549097826&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.16.2982

DO - 10.1200/JCO.2008.16.2982

M3 - Article

VL - 26

SP - 5094

EP - 5100

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 31

ER -